{"success":true,"data":{"pressRelease":{"id":"98777","rtpr_id":"nBw5h10jwa","ticker":"DTIL","exchange":"NASDAQ","all_tickers":["DTIL"],"title":"Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones","author":"Business Wire","published_at":"2026-07-27T11:01:00.068Z","article_body":"Precision BioSciences Announces Changes to Senior Leadership Team to Support\nAdvancement of Programs Through Next Set of Clinical Milestones\n\n– Leadership updates come as Precision advances its lead programs,\nPBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular\ndystrophy –\n\nPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing\ncompany utilizing its novel proprietary ARCUS(®) platform to develop in vivo\ngene editing therapies for high unmet need diseases, today announced changes\nto its senior leadership team. Alex Kelly, currently Chief Financial Officer,\nhas been promoted to the newly created role of Chief Operating Officer where\nhe will oversee all key customer-facing functions. Naresh Tanna, currently\nVice President of Investor Relations and Chief of Staff to the CEO, has been\npromoted to Chief Financial Officer where he will oversee corporate finance,\nreporting and investor relations. These two leadership changes will take\neffect beginning August 1, 2026. Cindy Atwell, Chief Development Officer,\ncontinues to lead clinical development across both of the Company’s clinical\nstage programs, PBGENE-HBV and PBGENE-DMD. To further support the development\nof two clinical stage programs, the Company has hired two new physician\nleaders under Ms. Atwell with proven expertise in infectious diseases and\nmuscular dystrophy. In addition, Cassie Gorsuch, PhD, Chief Scientific\nOfficer, now leads all research functions, including clinical stage\ntranslational sciences and next generation programs.\n\n“These leadership changes reflect the strength and depth of the team we have\nbuilt at Precision and our confidence in the leaders driving operational\nexcellence for our next phase of growth,” said Michael Amoroso, Chief\nExecutive Officer of Precision BioSciences. “As we continue to generate\nclinical data from the ELIMINATE-B and FUNCTION-DMD studies, Cassie, Cindy,\nAlex and Naresh are playing a central role in delivering our clinical promise\nto patients while driving shareholder value.”\n\nComplete biographies for each member of Precision’s leadership team are\navailable at https://precisionbiosciences.com/who-we-are/our-team/#leadership.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprecisionbiosciences.com%2Fwho-we-are%2Four-team%2F%23leadership&esheet=54577166&newsitemid=20260727263231&lan=en-US&anchor=https%3A%2F%2Fprecisionbiosciences.com%2Fwho-we-are%2Four-team%2F%23leadership.&index=1&md5=e585ca067fdc8d620f246216e384cb73)\n\nAbout Precision BioSciences, Inc.\n\nPrecision BioSciences, Inc. is a clinical stage gene editing company dedicated\nto improving life (DTIL) with its novel and proprietary ARCUS(®) genome\nediting platform that differs from other technologies in the way it cuts, its\nsmaller size, and its simpler structure. These features are intended for ARCUS\nnucleases to drive more defined therapeutic outcomes. Using ARCUS, the\nCompany’s pipeline is comprised of clinical stage in vivo gene editing\ncandidates designed to deliver lasting cures for the broadest range of genetic\nand infectious diseases where no adequate treatments exist. For more\ninformation about Precision BioSciences, please visit\nwww.precisionbiosciences.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.precisionbiosciences.com&esheet=54577166&newsitemid=20260727263231&lan=en-US&anchor=www.precisionbiosciences.com&index=2&md5=846421a7c747ac6ef345dfdad7604c12)\n.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. All statements contained\nin this press release that do not relate to matters of historical fact should\nbe considered forward-looking statements, including, without limitation,\nstatements regarding the Company’s leadership transitions, the anticipated\nroles and responsibilities of its executives, the advancement of its lead\nprograms toward future clinical milestones, and its external engagement\nefforts. These forward-looking statements are based on management’s current\nexpectations and are subject to risks and uncertainties that could cause\nactual results to differ materially from those expressed or implied. Factors\nthat could cause actual results to differ are described in the Company’s\nfilings with the U.S. Securities and Exchange Commission. Any forward-looking\nstatements speak only as of the date of this press release, and the Company\nundertakes no obligation to update or revise any forward-looking statements,\nexcept as required by law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260727263231/en/\n(https://www.businesswire.com/news/home/20260727263231/en/)\n\nInvestor and Media Contact: \n\nNaresh Tanna\n\nnaresh.tanna@precisionbiosciences.com\n(mailto:naresh.tanna@precisionbiosciences.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw5h10jwa","title":"Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones","author":"Business Wire","ticker":"DTIL","created":"2026-07-27T11:01:00.068Z","tickers":["DTIL"],"exchange":"NASDAQ","article_body":"Precision BioSciences Announces Changes to Senior Leadership Team to Support\nAdvancement of Programs Through Next Set of Clinical Milestones\n\n– Leadership updates come as Precision advances its lead programs,\nPBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular\ndystrophy –\n\nPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing\ncompany utilizing its novel proprietary ARCUS(®) platform to develop in vivo\ngene editing therapies for high unmet need diseases, today announced changes\nto its senior leadership team. Alex Kelly, currently Chief Financial Officer,\nhas been promoted to the newly created role of Chief Operating Officer where\nhe will oversee all key customer-facing functions. Naresh Tanna, currently\nVice President of Investor Relations and Chief of Staff to the CEO, has been\npromoted to Chief Financial Officer where he will oversee corporate finance,\nreporting and investor relations. These two leadership changes will take\neffect beginning August 1, 2026. Cindy Atwell, Chief Development Officer,\ncontinues to lead clinical development across both of the Company’s clinical\nstage programs, PBGENE-HBV and PBGENE-DMD. To further support the development\nof two clinical stage programs, the Company has hired two new physician\nleaders under Ms. Atwell with proven expertise in infectious diseases and\nmuscular dystrophy. In addition, Cassie Gorsuch, PhD, Chief Scientific\nOfficer, now leads all research functions, including clinical stage\ntranslational sciences and next generation programs.\n\n“These leadership changes reflect the strength and depth of the team we have\nbuilt at Precision and our confidence in the leaders driving operational\nexcellence for our next phase of growth,” said Michael Amoroso, Chief\nExecutive Officer of Precision BioSciences. “As we continue to generate\nclinical data from the ELIMINATE-B and FUNCTION-DMD studies, Cassie, Cindy,\nAlex and Naresh are playing a central role in delivering our clinical promise\nto patients while driving shareholder value.”\n\nComplete biographies for each member of Precision’s leadership team are\navailable at https://precisionbiosciences.com/who-we-are/our-team/#leadership.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprecisionbiosciences.com%2Fwho-we-are%2Four-team%2F%23leadership&esheet=54577166&newsitemid=20260727263231&lan=en-US&anchor=https%3A%2F%2Fprecisionbiosciences.com%2Fwho-we-are%2Four-team%2F%23leadership.&index=1&md5=e585ca067fdc8d620f246216e384cb73)\n\nAbout Precision BioSciences, Inc.\n\nPrecision BioSciences, Inc. is a clinical stage gene editing company dedicated\nto improving life (DTIL) with its novel and proprietary ARCUS(®) genome\nediting platform that differs from other technologies in the way it cuts, its\nsmaller size, and its simpler structure. These features are intended for ARCUS\nnucleases to drive more defined therapeutic outcomes. Using ARCUS, the\nCompany’s pipeline is comprised of clinical stage in vivo gene editing\ncandidates designed to deliver lasting cures for the broadest range of genetic\nand infectious diseases where no adequate treatments exist. For more\ninformation about Precision BioSciences, please visit\nwww.precisionbiosciences.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.precisionbiosciences.com&esheet=54577166&newsitemid=20260727263231&lan=en-US&anchor=www.precisionbiosciences.com&index=2&md5=846421a7c747ac6ef345dfdad7604c12)\n.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. All statements contained\nin this press release that do not relate to matters of historical fact should\nbe considered forward-looking statements, including, without limitation,\nstatements regarding the Company’s leadership transitions, the anticipated\nroles and responsibilities of its executives, the advancement of its lead\nprograms toward future clinical milestones, and its external engagement\nefforts. These forward-looking statements are based on management’s current\nexpectations and are subject to risks and uncertainties that could cause\nactual results to differ materially from those expressed or implied. Factors\nthat could cause actual results to differ are described in the Company’s\nfilings with the U.S. Securities and Exchange Commission. Any forward-looking\nstatements speak only as of the date of this press release, and the Company\nundertakes no obligation to update or revise any forward-looking statements,\nexcept as required by law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260727263231/en/\n(https://www.businesswire.com/news/home/20260727263231/en/)\n\nInvestor and Media Contact: \n\nNaresh Tanna\n\nnaresh.tanna@precisionbiosciences.com\n(mailto:naresh.tanna@precisionbiosciences.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-07-27T11:01:00.195963181Z","server_sent_at_ms":1785150060195},"received_at":"2026-07-27T11:01:00.247Z","source_url":"https://www.businesswire.com/news/home/20260727263231/en/"},"analysis":{"id":"87813","press_release_id":"98777","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Precision BioSciences announced leadership changes effective August 1, 2026, promoting current CFO Alex Kelly to the newly created Chief Operating Officer role and Vice President Naresh Tanna to Chief Financial Officer.\n\nThe restructuring is designed to support the advancement of the company's lead clinical programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy.\n\nCEO Michael Amoroso highlighted that the moves reflect the strength of the leadership team as the company prepares to deliver clinical data from the ELIMINATE-B and FUNCTION-DMD studies.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Internal promotions signal operational readiness as clinical data readouts approach."},"keyFigures":null,"quotedText":"These leadership changes reflect the strength and depth of the team we have built at Precision and our confidence in the leaders driving operational excellence for our next phase of growth","namedEntities":{"people":[{"name":"Alex Kelly","role":"Chief Operating Officer"},{"name":"Naresh Tanna","role":"Chief Financial Officer"},{"name":"Michael Amoroso","role":"Chief Executive Officer"},{"name":"Cindy Atwell","role":"Chief Development Officer"},{"name":"Cassie Gorsuch","role":"Chief Scientific Officer"}],"products":["PBGENE-HBV","PBGENE-DMD","ARCUS"],"companies":[{"name":"Precision BioSciences, Inc.","ticker":"DTIL"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Internal promotions including the transition of the CFO to COO and elevation of the VP of Investor Relations to CFO. While CFO changes are material, these are planned internal promotions supporting pipeline progression rather than abrupt departures."},"tickerRelevance":{"others":[],"primary":"DTIL"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap-biotech","eventGravity":"executive_promotion"}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Precision BioSciences announced leadership changes effective August 1, 2026, promoting current CFO Alex Kelly to the newly created Chief Operating Officer role and Vice President Naresh Tanna to Chief Financial Officer.\n\nThe restructuring is designed to support the advancement of the company's lead clinical programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy.\n\nCEO Michael Amoroso highlighted that the moves reflect the strength of the leadership team as the company prepares to deliver clinical data from the ELIMINATE-B and FUNCTION-DMD studies.","key_figures":null,"named_entities":{"people":[{"name":"Alex Kelly","role":"Chief Operating Officer"},{"name":"Naresh Tanna","role":"Chief Financial Officer"},{"name":"Michael Amoroso","role":"Chief Executive Officer"},{"name":"Cindy Atwell","role":"Chief Development Officer"},{"name":"Cassie Gorsuch","role":"Chief Scientific Officer"}],"products":["PBGENE-HBV","PBGENE-DMD","ARCUS"],"companies":[{"name":"Precision BioSciences, Inc.","ticker":"DTIL"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-27T11:29:01.098Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"small-mid-cap-biotech","eventGravity":"executive_promotion"}},"durationMs":137619,"modelName":"glm-4.7"}}